An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
NCT03777436
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
289
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
Apremilast
OTHER:
Placebo
Sponsor
Amgen